Form 4 Filing for BioStem Technologies, Inc.

This filing details transactions by Andrew Smith-Van Vurst, Chief Operating Officer, Director, and 10% owner of BioStem Technologies, Inc. On October 7, 2026, Mr. Smith-Van Vurst acquired 250,000 shares of Common Stock at $2.00 per share, increasing his post-transaction holdings to 1,789,809 shares. Additionally, he disposed of 250,000 shares of "Options (Right to Buy)" with an exercise price of $2.00, resulting in 2,000,000 shares held post-transaction. The filing also lists various derivative holdings, including Series A-1 Convertible Preferred Shares, options with different vesting schedules and exercise prices, and restricted stock units with varying vesting terms, all related to the Common Stock of BioStem Technologies, Inc.